LYN

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Retrieved on: 
Monday, February 12, 2024
B cell, Therapy, Allergy, Protein, SAN, Immunoglobulin E, SCF, LYN, JAK1, Stem cell factor, Vaccine

SAN CARLOS, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publication of new scientific results in Allergy.  The preclinical research found that AK006 (agonist Siglec-6 antibody) impacts mast cell function by interacting with multiple activating receptors and key signaling molecules.

Key Points: 
  • The preclinical research found that AK006 (agonist Siglec-6 antibody) impacts mast cell function by interacting with multiple activating receptors and key signaling molecules.
  • The publication titled “Regulation of Mast Cells by Overlapping but Distinct Protein Interactions of Siglec-6 and Siglec-8” details efforts to identify proteins associated with Siglec-6 and Siglec-8 in mast cells and functionally characterize these protein interaction networks using ex vivo and in vivo models of mast cell activation.
  • The data published today add to previously published preclinical data demonstrating that AK006 inhibits multiple modes of mast activation.
  • These findings suggest Siglec-6 has a broader role in regulating mast cell function and may contribute to the increased inhibitory effects observed with AK006 in vitro and in vivo.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

Burnbrae Farms unveils two new sustainable shell egg offerings, produced using 100 percent clean solar energy

Retrieved on: 
Wednesday, November 1, 2023
DHA, Heart, Farm, Grain boundary strengthening, Vitamin, Carbon, Electricity, Environment, Egg, Burnbrae Farms, Immune system, Lighting, Mineral, Animal, Diet, Brain, Ventilation, Lutein, Atlantic Canada, LYN

LYN, Ontario, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Burnbrae Farms, Canada’s leading family-owned and operated egg company, is proud to launch two new specialty products: Naturegg Solar Free Range and Naturegg Omega Plus Solar Free Range eggs, offering Canadians even more nutritious and sustainable options in their grocery stores.

Key Points: 
  • LYN, Ontario, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Burnbrae Farms, Canada’s leading family-owned and operated egg company, is proud to launch two new specialty products: Naturegg Solar Free Range and Naturegg Omega Plus Solar Free Range eggs, offering Canadians even more nutritious and sustainable options in their grocery stores.
  • Tracking its carbon footprint since 2018, Burnbrae Farms is continuing to focus on making an even greater impact, with the reduction of greenhouse gas emissions and electricity consumption across its farms.
  • “At Burnbrae Farms, we recognize that a lot goes into a little,” said Margaret Hudson, President and CEO, Burnbrae Farms.
  • Naturegg Omega Plus Solar Free Range and Naturegg Solar Free Range eggs are available in the eggs section of select grocery stores across Ontario, Quebec and Atlantic Canada.

Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH, Featuring Breakthroughs in Lymphoma Treatment

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Janus, DLBCL, Trial of the century, JAK1, Progression-free survival, DOR, CSF, Human, PTCL, 65th United States Congress, PFS, B-cell lymphoma, LYN, Society, ASH, Hematology, Traffic barrier, BBB, Janus kinase 1, Relapse, Peripheral, ORR, NDA, BTK, Patient, Prognosis, ASCO, TAI, Pharmaceutical industry, Vaccine

Golidocitinib is the first and only Janus kinase 1 (JAK1) selective inhibitor in the NDA stage for the treatment of r/r PTCL.

Key Points: 
  • Golidocitinib is the first and only Janus kinase 1 (JAK1) selective inhibitor in the NDA stage for the treatment of r/r PTCL.
  • Golidocitinib monotherapy demonstrated superior efficacy and safety profile in the full analysis of the JACKPOT8 PARTB study, which was consistent with the preliminary findings presented at 2023 ASCO.
  • The pooled analysis results from these two studies will be presented for the first time at 2023 ASH.
  • Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Thursday, March 23, 2023
ASH, Lux, APS, Controller, ITD, TKD, G1, BCR, Associate, Accounting, Plasma, RAS, Investment, Patient, RUNX1, Clinical, LYN, TP53, DNMT3A, SYK, European Hematology Association, Research, Aplastic anemia, MRD, BCL2, PLOS One, MLL, Data, FLT3, TSX, Amylin Pharmaceuticals, FDA, Combination, RSK, Lymphoid leukemia, Absorption, BTK, Acute myeloid leukemia, Phase 1, CR, Hand, MD Anderson Cancer Center, Inflammation, Lymphoma, Phosphorylation, National university, NPM1, Clinical trial, European School, Data monitoring committee, AML, BID, EHA, ISTA Pharmaceuticals, Harvard Business School, Toxic leukoencephalopathy, G3, Gene, Society, Pharmaceutical industry, Cryptocurrency, Vaccine, Running

SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.
  • Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million.
  • Aptose Appoints VP, Controller – During the fourth quarter, Aptose appointed Brooks Ensign, Vice President and Controller.
  • A summary of the results of operations for the years ended December 31, 2022 and 2021 is presented below:

Burnbrae Farms - proudly certified as a Women's Business Enterprise

Retrieved on: 
Thursday, October 13, 2022
WBE, Burnbrae Farms, Egg, Certification, McFall, Business, CEO, Woman, Sibling, Livestock, LYN

LYN, ON, Oct. 13, 2022 /CNW/ - Burnbrae Farms, a leader in the Canadian food industry and a national supplier of eggs and egg products, proudly announces that it is certified as a Women's Business Enterprise (WBE).

Key Points: 
  • LYN, ON, Oct. 13, 2022 /CNW/ - Burnbrae Farms, a leader in the Canadian food industry and a national supplier of eggs and egg products, proudly announces that it is certified as a Women's Business Enterprise (WBE).
  • Canadian businesses that are at least 51 per cent owned and managed by women are eligible to be WBE Canada certified.
  • AsCanada'sleading egg marketer, Burnbrae Farms is committed to offering safe, nutritious and affordable eggs and egg products to Canadians.
  • Burnbrae Farms is a sixth-generation family-owned and operated Canadian company that has been producing eggs and egg products for almost 80 years.

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

Retrieved on: 
Monday, May 2, 2022
Drug development, Toxicity, Monocyte, Lymphoid leukemia, Risk, Chronic lymphocytic leukemia, Skin, Exchange, Microdeletion syndrome, Cell death, TSX, APS, Phosphorylation, NLRP3, NASDAQ, PDX, Mantle cell lymphoma, Mitophagy, Company, Patient, SYK, Research, Inflammation, SAN, Therapy, CLL, Venetoclax, IL-6, BTK, Inflammasome, TP53, Acute myeloid leukemia, RAS, GMP, TEC, ERK, Publication, Hematology, MDS, NHL, U.S. Securities and Exchange Commission, LYN, Toxic epidermal necrolysis, COVID-19, Cytokine, ERBB2, NPM1, AML, GLOBE, MCL, Apoptosis, Cancer, Lymphatic system, EGFR, TLR, ASXL1, American Association for Cancer Research, THP-1 cell line, Pharmaceutical industry, Vaccine, Sulfur, Food preservation, FLT3

Luxeptinib does not impede the assembly of the NLRP3-ASC complex but does potently inhibit three kinases phosphorylated in response to endotoxin.

Key Points: 
  • Luxeptinib does not impede the assembly of the NLRP3-ASC complex but does potently inhibit three kinases phosphorylated in response to endotoxin.
  • Luxeptinib also inhibits the release of TNF and IL-6 in response to activation of the TLR pathway without affecting the TLR/IRAK/MyD88 proteins.
  • Luxeptinib induced apoptosis in ibrutinib-resistant MCL cell lines, and in primary MCL cells luxeptinib downmodulated anti-apoptotic proteins Mcl-1 and Bcl-xL and reversed stromal cell survival effects.
  • Oral luxeptinib demonstrated strong antitumor activity in preclinical in vivo AML xenograft models but no myelosuppression or evidence of tissue damage in acute toxicology studies.

Burnbrae Farms commits to net zero carbon emissions by 2050, introduces second solar powered egg farm and its first public Sustainability Report

Retrieved on: 
Friday, April 22, 2022
Water, Family, CEO, Carbon, Egg, Burnbrae Farms, List of The Vicar of Dibley episodes, Electricity, Greenhouse, Sustainability reporting, Environment, Renewable energy, Livestock, Agriculture, LYN

The report provides a summary of Burnbrae Farms' sustainability objectives and progress against its five key pillars: Environment, Animal Care, Health & Wellbeing, Safe Nourishing Food, and Community Spirit.

Key Points: 
  • The report provides a summary of Burnbrae Farms' sustainability objectives and progress against its five key pillars: Environment, Animal Care, Health & Wellbeing, Safe Nourishing Food, and Community Spirit.
  • As part of the company's work to reduce its environmental impact, today, Burnbrae Farms is announcing its commitment to achieving net zero carbon emissions by 2050.
  • Learn more about Burnbrae Farms' sustainability initiatives in its first public Sustainability Report, " Eggs For Life ".
  • Burnbrae Farms is a sixth-generation family-owned and operated Canadian company that has been producing eggs and egg products for almost 80 years.

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Tyrosine kinases, B-cell receptor, Tyrosine-protein kinase SYK, LYN, Clinical endpoint, Progression-free survival, Signal transduction

The primary endpoint is objective response rate (\xe2\x80\x9cORR\xe2\x80\x9d), with secondary endpoints including complete response rate (CRR), progression-free survival (PFS), time to response (TTR) and duration of response (DoR).

Key Points: 
  • The primary endpoint is objective response rate (\xe2\x80\x9cORR\xe2\x80\x9d), with secondary endpoints including complete response rate (CRR), progression-free survival (PFS), time to response (TTR) and duration of response (DoR).
  • The trial is being conducted in over 35 sites in China.
  • Upon an antigen binding to B-cell receptors, PI3K\xce\xb4 can be activated through the Lyn and Syk signaling cascade.
  • For further discussion of these and other risks, see HUTCHMED\xe2\x80\x99s filings with the U.S. Securities and Exchange Commission and on AIM.

Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic

Retrieved on: 
Tuesday, March 9, 2021
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Pharmaceutical industry, Chemical compounds, Health care, Melior Discovery, Tolimidone, Melior, Drug discovery, LYN, Drug repositioning, Investigational New Drug, Medication

Melior Pharmaceuticals (Melior) announced that it has received clearance of its Investigational New Drug (IND) application for the clinical development of its novel, first-in-class lyn kinase activator, tolimidone, for the treatment of COVID-19.

Key Points: 
  • Melior Pharmaceuticals (Melior) announced that it has received clearance of its Investigational New Drug (IND) application for the clinical development of its novel, first-in-class lyn kinase activator, tolimidone, for the treatment of COVID-19.
  • As with all of Meliors drug candidates, this is a repositioned drug that has been shown to be safe and well-tolerated in previous clinical studies.
  • Melior Discovery and its sister company, Melior Pharmaceuticals, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .